ArticleJACS Au2026
Dexter Energy Transfer Photocatalytic Microdissection of Amyloid Plaques in Alzheimer's Disease.
Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent Advances in Photocatalyst-Driven Protein Labeling and Proximity Mapping.Chemical record (New York, N.Y.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloid plaque is a pathological hallmark in Alzheimer's disease (AD) brain with its composition associated with disease etiology. Here, we report a photocatalyst, namely, AmyCAT, that selectively binds to amyloid fibrils in AD brain tissues and undergoes Dexter energy transfer (DET) to catalyze carbene production for amyloid proximity labeling. First, we designed the AmyCAT photocatalyst to universally bind different types of amyloids. Second, we energetically match the DET effect in a 12 × 4 photocatalyst-substrate array to activate the diazo substrate into reactive carbene species by visible green light (530-545 nm). Further, we demonstrate that the optimal AmyCAT probe catalyzes pan-amyloid protein labeling with a 30-fold selectivity over folded counterparts. Mechanistic studies confirm that the photocatalytic labeling is indeed via the DET process, which tailors the proximity effect for spatially confined amyloid labeling. Finally, we employ the AmyCAT photocatalyst to label, enrich, and profile amyloid plaques in AD brain tissues, identifying key proteins and pathways associated with AD pathological deposition and etiology. The small-molecule-based strategy reported herein dispenses with the antibody, genetic modification, or microscopes to dissect and profile amyloid deposits from AD tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.